Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 144
Filter
1.
Int J Neuropsychopharmacol ; 24(3): 191-199, 2021 03 17.
Article in English | MEDLINE | ID: mdl-33125470

ABSTRACT

BACKGROUND: The serotonin transporter gene (SLC6A4; 5-HTT; SERT) is considered a prime candidate in pharmacogenetic research in major depressive disorder (MDD). Besides genetic variation, recent advances have spotlighted the involvement of epigenetic mechanisms such as DNA methylation in predicting antidepressant treatment response in "pharmaco-epigenetic" approaches. In MDD, lower SLC6A4 promoter methylation has been suggested to predict impaired response to serotonergic antidepressants. The present study sought to replicate and extend this finding in a large, independent sample of MDD patients. METHODS: The sample comprised n = 236 Caucasian patients with MDD receiving antidepressant medication in a naturalistic treatment setting. Functional DNA methylation of 9 CpG sites located in the SLC6A4 promoter region was analyzed via direct sequencing of sodium bisulfite- treated DNA extracted from blood cells. Patients were assessed over the course of a 6-week in-patient treatment using the Hamilton Depression Scale (HAM-D). RESULTS: Results confirm relative SLC6A4 hypomethylation to predict impaired antidepressant response both dimensionally and categorically (HAM-D reductions < 50%) and to furthermore be indicative of nonremission (HAM-D > 7). This also held true in a homogenous subgroup of patients continuously treated with selective serotonin reuptake inhibitors or serotonin/noradrenaline reuptake inhibitors (n = 110). CONCLUSIONS: Impaired response to serotonergic antidepressants via SLC6A4 hypomethylation may be conveyed by increased gene expression and consequently decreased serotonin availability, which may counteract the effects of serotonergic antidepressants. The present results could in the future inform clinical decision-making towards a more personalized treatment of MDD.


Subject(s)
Antidepressive Agents/pharmacology , DNA Methylation/genetics , Depressive Disorder, Major/drug therapy , Depressive Disorder, Major/genetics , Serotonin Plasma Membrane Transport Proteins/genetics , Adult , Aged , CpG Islands , Female , Humans , Male , Middle Aged , Pharmacogenetics , Pharmacogenomic Testing , Promoter Regions, Genetic
2.
Brain Behav Immun ; 67: 203-210, 2018 Jan.
Article in English | MEDLINE | ID: mdl-28867280

ABSTRACT

Major depressive disorder (MDD) is a prevalent disorder with moderate heritability. Both MDD and interpersonal adversity, including childhood maltreatment, have been consistently associated with elevated inflammatory markers. We investigated interaction between exposure to childhood maltreatment and extensive genetic variation within the inflammation pathway (CRP, IL1b, IL-6, IL11, TNF, TNFR1, and TNFR2) in relation to depression diagnosis. The discovery RADIANT sample included 262 cases with recurrent DSM-IV/ICD-10 MDD, and 288 unaffected controls. The replication Münster cohort included 277 cases with DSM-IV MDD, and 316 unaffected controls. We identified twenty-five single nucleotide polymorphisms (SNPs) following multiple testing correction that interacted with childhood maltreatment to predict depression in the discovery cohort. Seven SNPs representing independent signals (rs1818879, rs1041981, rs4149576, rs616645, rs17882988, rs1061622, and rs3093077) were taken forward for replication. Meta-analyses of the two samples presented evidence for interaction with rs1818879 (IL6) (RD=0.059, SE=0.016, p<0.001), with the replication Münster sample approaching statistical significance in analyses restricted to recurrent MDD and controls following correction for multiple testing (q=0.066). The CRP locus (rs3093077) showed a similar level of evidence for interaction in the meta-analysis (RD=0.092, SE=0.029, p=0.002), but less compelling evidence in the replication sample alone (recurrent MDD q=0.198; all MDD q=0.126). Here we present evidence suggestive of interaction with childhood maltreatment for novel loci in IL-6 (rs1818879) and CRP (rs3093077), increasing risk of depression. Replication is needed by independent groups, targeting these specific variants and interaction with childhood maltreatment on depression risk.


Subject(s)
Depressive Disorder, Major/genetics , Depressive Disorder, Major/immunology , Inflammation/genetics , Inflammation/immunology , Adult , Adult Survivors of Child Abuse , C-Reactive Protein/genetics , Case-Control Studies , Depressive Disorder, Major/complications , Female , Gene-Environment Interaction , Genotype , Humans , Inflammation/complications , Inflammation Mediators/metabolism , Interleukin-6/genetics , Male , Middle Aged , Polymorphism, Single Nucleotide , Risk Factors
3.
Mol Psychiatry ; 22(7): 1015-1025, 2017 07.
Article in English | MEDLINE | ID: mdl-27777418

ABSTRACT

Major depressive disorder (MDD) affects around 350 million people worldwide; however, the underlying genetic basis remains largely unknown. In this study, we took into account that MDD is a gene-environment disorder, in which stress is a critical component, and used whole-genome screening of functional variants to investigate the 'missing heritability' in MDD. Genome-wide association studies (GWAS) using single- and multi-locus linear mixed-effect models were performed in a Los Angeles Mexican-American cohort (196 controls, 203 MDD) and in a replication European-ancestry cohort (499 controls, 473 MDD). Our analyses took into consideration the stress levels in the control populations. The Mexican-American controls, comprised primarily of recent immigrants, had high levels of stress due to acculturation issues and the European-ancestry controls with high stress levels were given higher weights in our analysis. We identified 44 common and rare functional variants associated with mild to moderate MDD in the Mexican-American cohort (genome-wide false discovery rate, FDR, <0.05), and their pathway analysis revealed that the three top overrepresented Gene Ontology (GO) processes were innate immune response, glutamate receptor signaling and detection of chemical stimulus in smell sensory perception. Rare variant analysis replicated the association of the PHF21B gene in the ethnically unrelated European-ancestry cohort. The TRPM2 gene, previously implicated in mood disorders, may also be considered replicated by our analyses. Whole-genome sequencing analyses of a subset of the cohorts revealed that European-ancestry individuals have a significantly reduced (50%) number of single nucleotide variants compared with Mexican-American individuals, and for this reason the role of rare variants may vary across populations. PHF21b variants contribute significantly to differences in the levels of expression of this gene in several brain areas, including the hippocampus. Furthermore, using an animal model of stress, we found that Phf21b hippocampal gene expression is significantly decreased in animals resilient to chronic restraint stress when compared with non-chronically stressed animals. Together, our results reveal that including stress level data enables the identification of novel rare functional variants associated with MDD.


Subject(s)
Depressive Disorder, Major/genetics , Adult , Case-Control Studies , Female , Gene Expression , Genetic Predisposition to Disease/genetics , Genome-Wide Association Study , Humans , Los Angeles , Male , Mexican Americans/genetics , Middle Aged , Polymorphism, Single Nucleotide/genetics , Risk Factors , Stress, Psychological , White People/genetics
4.
Mol Psychiatry ; 22(5): 703-710, 2017 05.
Article in English | MEDLINE | ID: mdl-28348383

ABSTRACT

Genetic and neuroimaging research has identified neurobiological correlates of obesity. However, evidence for an integrated model of genetic risk and brain structural alterations in the pathophysiology of obesity is still absent. Here we investigated the relationship between polygenic risk for obesity, gray matter structure and body mass index (BMI) by the use of univariate and multivariate analyses in two large, independent cohorts (n=330 and n=347). Higher BMI and higher polygenic risk for obesity were significantly associated with medial prefrontal gray matter decrease, and prefrontal gray matter was further shown to significantly mediate the effect of polygenic risk for obesity on BMI in both samples. Building on this, the successful individualized prediction of BMI by means of multivariate pattern classification algorithms trained on whole-brain imaging data and external validations in the second cohort points to potential clinical applications of this imaging trait marker.


Subject(s)
Gray Matter/anatomy & histology , Gray Matter/physiology , Obesity/genetics , Prefrontal Cortex/anatomy & histology , Prefrontal Cortex/physiology , Adult , Algorithms , Body Mass Index , Brain Mapping/methods , Female , Genetic Predisposition to Disease , Gray Matter/diagnostic imaging , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Neuroimaging , Obesity/etiology , Obesity/pathology , Prefrontal Cortex/diagnostic imaging , Risk Factors
5.
Mol Psychiatry ; 22(10): 1431-1439, 2017 10.
Article in English | MEDLINE | ID: mdl-28167838

ABSTRACT

The molecular genetics of panic disorder (PD) with and without agoraphobia (AG) are still largely unknown and progress is hampered by small sample sizes. We therefore performed a genome-wide association study with a dimensional, PD/AG-related anxiety phenotype based on the Agoraphobia Cognition Questionnaire (ACQ) in a sample of 1370 healthy German volunteers of the CRC TRR58 MEGA study wave 1. A genome-wide significant association was found between ACQ and single non-coding nucleotide variants of the GLRB gene (rs78726293, P=3.3 × 10-8; rs191260602, P=3.9 × 10-8). We followed up on this finding in a larger dimensional ACQ sample (N=2547) and in independent samples with a dichotomous AG phenotype based on the Symptoms Checklist (SCL-90; N=3845) and a case-control sample with the categorical phenotype PD/AG (Ncombined =1012) obtaining highly significant P-values also for GLRB single-nucleotide variants rs17035816 (P=3.8 × 10-4) and rs7688285 (P=7.6 × 10-5). GLRB gene expression was found to be modulated by rs7688285 in brain tissue, as well as cell culture. Analyses of intermediate PD/AG phenotypes demonstrated increased startle reflex and increased fear network, as well as general sensory activation by GLRB risk gene variants rs78726293, rs191260602, rs17035816 and rs7688285. Partial Glrb knockout mice demonstrated an agoraphobic phenotype. In conjunction with the clinical observation that rare coding GLRB gene mutations are associated with the neurological disorder hyperekplexia characterized by a generalized startle reaction and agoraphobic behavior, our data provide evidence that non-coding, although functional GLRB gene polymorphisms may predispose to PD by increasing startle response and agoraphobic cognitions.


Subject(s)
Agoraphobia/genetics , Agoraphobia/metabolism , Receptors, Glycine/genetics , Adult , Alleles , Anxiety/complications , Anxiety Disorders/genetics , Brain/metabolism , Brain/physiology , Case-Control Studies , Cognition/physiology , Fear/physiology , Fear/psychology , Female , Gene Frequency/genetics , Genetic Predisposition to Disease/genetics , Genome-Wide Association Study , Genotype , Germany , Humans , Male , Mutation/genetics , Panic Disorder/genetics , Receptors, Glycine/metabolism , Reflex, Startle/genetics
6.
Mol Psychiatry ; 22(6): 900-909, 2017 06.
Article in English | MEDLINE | ID: mdl-27137745

ABSTRACT

The neuro-anatomical substrates of major depressive disorder (MDD) are still not well understood, despite many neuroimaging studies over the past few decades. Here we present the largest ever worldwide study by the ENIGMA (Enhancing Neuro Imaging Genetics through Meta-Analysis) Major Depressive Disorder Working Group on cortical structural alterations in MDD. Structural T1-weighted brain magnetic resonance imaging (MRI) scans from 2148 MDD patients and 7957 healthy controls were analysed with harmonized protocols at 20 sites around the world. To detect consistent effects of MDD and its modulators on cortical thickness and surface area estimates derived from MRI, statistical effects from sites were meta-analysed separately for adults and adolescents. Adults with MDD had thinner cortical gray matter than controls in the orbitofrontal cortex (OFC), anterior and posterior cingulate, insula and temporal lobes (Cohen's d effect sizes: -0.10 to -0.14). These effects were most pronounced in first episode and adult-onset patients (>21 years). Compared to matched controls, adolescents with MDD had lower total surface area (but no differences in cortical thickness) and regional reductions in frontal regions (medial OFC and superior frontal gyrus) and primary and higher-order visual, somatosensory and motor areas (d: -0.26 to -0.57). The strongest effects were found in recurrent adolescent patients. This highly powered global effort to identify consistent brain abnormalities showed widespread cortical alterations in MDD patients as compared to controls and suggests that MDD may impact brain structure in a highly dynamic way, with different patterns of alterations at different stages of life.


Subject(s)
Cerebral Cortex/pathology , Depressive Disorder, Major/diagnostic imaging , Depressive Disorder, Major/pathology , Adolescent , Adult , Brain/pathology , Cerebral Cortex/diagnostic imaging , Female , Frontal Lobe/pathology , Gray Matter/pathology , Gyrus Cinguli/pathology , Humans , Magnetic Resonance Imaging/methods , Male , Neuroimaging/methods , Neuroimaging/psychology , Prefrontal Cortex/pathology , Temporal Lobe/pathology
7.
J Neural Transm (Vienna) ; 125(2): 229-238, 2018 02.
Article in English | MEDLINE | ID: mdl-29159580

ABSTRACT

The amygdala plays a crucial role in the pathogenesis of major depressive disorder (MDD). While robust findings support a negative impact of illness duration on hippocampal volume in MDD, morphometric studies of the amygdala have yielded inhomogeneous results. Considering the methodical problems of automatic segmentation methods, a standardized segmentation protocol with proven inter- and intra-rater reliability was employed using high-resolution magnetic resonance imaging. To identify the effect of MDD on amygdala morphometry, 23 unipolar depressed patients who responded to antidepressant medication and 30 age-matched healthy controls (HC) were enrolled. First, gray matter volumes (GMV) of the bilateral amygdala were delineated manually in 3D by three blinded experts using the MultiTracer. The whole brain GMV was determined by using voxel-based morphometry. Second, the differences of the whole brain and the bilateral amygdala GMV values between MDD and HC were calculated with t-statistics. The GMV of the whole brain and the amygdala did not differ between HC and MDD patients. Third, MDD characteristics were correlated with amygdala GMV. Within the normal range, the left amygdala GMV was larger in patients with later onset and smaller in cases of prolonged depression. In line with prior reports of depressed patients responding to antidepressant treatment, amygdala GMV was negatively related to illness duration, suggesting volume loss with disease progression. It remains unclear as to whether the association between illness duration and GMV reduced left amygdala volume indicates a neurotoxic effect of prolonged MDD or is rather a negative predictor of chronic depression.


Subject(s)
Amygdala/pathology , Depressive Disorder, Major/pathology , Adult , Aged , Amygdala/diagnostic imaging , Depressive Disorder, Major/diagnostic imaging , Female , Humans , Image Interpretation, Computer-Assisted/methods , Imaging, Three-Dimensional/methods , Magnetic Resonance Imaging/methods , Male , Middle Aged , Neuroimaging/methods
8.
Nervenarzt ; 89(1): 99-112, 2018 Jan.
Article in German | MEDLINE | ID: mdl-28932896

ABSTRACT

Autoimmune encephalitis is a group of autoimmune inflammatory disorders affecting both grey and white matter of the central nervous system. Encephalitis with autoantibodies against the N­methyl-D-aspartate receptor (NMDA-R) is the most frequent autoimmune encephalitis syndrome presenting with a characteristic sequence of psychiatric and neurological symptoms. Treatment necessitates a close interdisciplinary cooperation. This article provides an update on the current knowledge on diagnostic standards, pathogenesis, and treatment strategies for anti-NMDA-R encephalitis from psychiatric and neurological perspectives.


Subject(s)
Anti-N-Methyl-D-Aspartate Receptor Encephalitis/immunology , Anti-N-Methyl-D-Aspartate Receptor Encephalitis/therapy , Autoantibodies/blood , Receptors, N-Methyl-D-Aspartate/immunology , Anti-N-Methyl-D-Aspartate Receptor Encephalitis/diagnosis , Anti-N-Methyl-D-Aspartate Receptor Encephalitis/psychology , Cognition Disorders/diagnosis , Cognition Disorders/immunology , Cognition Disorders/psychology , Cognition Disorders/therapy , Diagnosis, Differential , Female , Humans , Interdisciplinary Communication , Intersectoral Collaboration , Male , Mental Disorders/diagnosis , Mental Disorders/immunology , Mental Disorders/psychology , Mental Disorders/therapy , Neuralgia, Postherpetic/diagnosis , Neuralgia, Postherpetic/immunology , Neuralgia, Postherpetic/psychology , Neuralgia, Postherpetic/therapy , Ovarian Neoplasms/diagnosis , Ovarian Neoplasms/immunology , Ovarian Neoplasms/therapy , Paraneoplastic Syndromes/diagnosis , Paraneoplastic Syndromes/immunology , Paraneoplastic Syndromes/psychology , Paraneoplastic Syndromes/therapy , Prognosis , Teratoma/immunology , Young Adult
9.
Psychol Med ; 47(12): 2166-2176, 2017 Sep.
Article in English | MEDLINE | ID: mdl-28397635

ABSTRACT

BACKGROUND: Electroconvulsive therapy (ECT) is one of the most effective treatments for severe depression. However, little is known regarding brain functional processes mediating ECT effects. METHOD: In a non-randomized prospective study, functional magnetic resonance imaging data during the automatic processing of subliminally presented emotional faces were obtained twice, about 6 weeks apart, in patients with major depressive disorder (MDD) before and after treatment with ECT (ECT, n = 24). Additionally, a control sample of MDD patients treated solely with pharmacotherapy (MED, n = 23) and a healthy control sample (HC, n = 22) were obtained. RESULTS: Before therapy, both patient groups equally showed elevated amygdala reactivity to sad faces compared with HC. After treatment, a decrease in amygdala activity to negative stimuli was discerned in both patient samples indicating a normalization of amygdala function, suggesting mechanisms potentially unspecific for ECT. Moreover, a decrease in amygdala activity to sad faces was associated with symptomatic improvements in the ECT sample (r spearman = -0.48, p = 0.044), and by tendency also for the MED sample (r spearman = -0.38, p = 0.098). However, we did not find any significant association between pre-treatment amygdala function to emotional stimuli and individual symptom improvement, neither for the ECT sample, nor for the MED sample. CONCLUSIONS: In sum, the present study provides first results regarding functional changes in emotion processing due to ECT treatment using a longitudinal design, thus validating and extending our knowledge gained from previous treatment studies. A limitation was that ECT patients received concurrent medication treatment.


Subject(s)
Amygdala/physiopathology , Depressive Disorder, Major/physiopathology , Depressive Disorder, Major/therapy , Electroconvulsive Therapy/methods , Magnetic Resonance Imaging/methods , Outcome Assessment, Health Care , Adult , Amygdala/diagnostic imaging , Depressive Disorder, Major/diagnostic imaging , Facial Expression , Female , Follow-Up Studies , Humans , Male , Middle Aged , Prospective Studies
10.
Mol Psychiatry ; 21(6): 813-22, 2016 06.
Article in English | MEDLINE | ID: mdl-26324098

ABSTRACT

Corticotropin-releasing hormone (CRH) is a major regulator of the hypothalamic-pituitary-adrenal axis. Binding to its receptor CRHR1 triggers the downstream release of the stress response-regulating hormone cortisol. Biochemical, behavioral and genetic studies revealed CRHR1 as a possible candidate gene for mood and anxiety disorders. Here we aimed to evaluate CRHR1 as a risk factor for panic disorder (PD). Allelic variation of CRHR1 was captured by 9 single-nucleotide polymorphisms (SNPs), which were genotyped in 531 matched case/control pairs. Four SNPs were found to be associated with PD, in at least one sub-sample. The minor allele of rs17689918 was found to significantly increase risk for PD in females after Bonferroni correction and furthermore decreased CRHR1 mRNA expression in human forebrains and amygdalae. When investigating neural correlates underlying this association in patients with PD using functional magnetic resonance imaging, risk allele carriers of rs17689918 showed aberrant differential conditioning predominantly in the bilateral prefrontal cortex and safety signal processing in the amygdalae, arguing for predominant generalization of fear and hence anxious apprehension. Additionally, the risk allele of rs17689918 led to less flight behavior during fear-provoking situations but rather increased anxious apprehension and went along with increased anxiety sensitivity. Thus reduced gene expression driven by CRHR1 risk allele leads to a phenotype characterized by fear sensitization and hence sustained fear. These results strengthen the role of CRHR1 in PD and clarify the mechanisms by which genetic variation in CRHR1 is linked to this disorder.


Subject(s)
Panic Disorder/genetics , Receptors, Corticotropin-Releasing Hormone/genetics , Adult , Alleles , Anxiety/genetics , Anxiety Disorders/genetics , Bias , Corticotropin-Releasing Hormone/metabolism , Fear , Female , Genetic Predisposition to Disease/genetics , Genetic Variation/genetics , Genotype , Humans , Hydrocortisone/metabolism , Hypothalamo-Hypophyseal System/metabolism , Male , Middle Aged , Phenotype , Pituitary-Adrenal System/metabolism , Polymorphism, Single Nucleotide , Risk Factors
11.
Eur Arch Psychiatry Clin Neurosci ; 267(8): 767-779, 2017 Dec.
Article in English | MEDLINE | ID: mdl-28337537

ABSTRACT

Previous studies suggest an inhibitory top-down control of the amygdala by the prefrontal cortex (PFC). Both brain regions play a role in the modulation of prepulse modification (PPM) of the acoustic startle response by a pre-stimulus. Repetitive transcranial magnetic stimulation (rTMS) can modulate the activity of the PFC and might thus affect PPM. This study tested the effect of inhibitory rTMS on PPM accounting for a genetic variant of the dopamine transporter gene (DAT1). Healthy participants (N = 102) were stimulated with continuous theta burst stimulation (cTBS, an intense form of inhibitory rTMS) or sham treatment over the right PFC. Afterwards, during continuous presentation of a background white noise a louder noise burst was presented either alone (control startle) or preceded by a prepulse. Participants were genotyped for a DAT1 variable number tandem repeat (VNTR) polymorphism. Two succeeding sessions of cTBS over the right PFC (2 × 600 stimuli with a time lag of 15 min) attenuated averaged prepulse inhibition (PPI) in participants with a high resting motor threshold. An attenuation of PPI induced by prepulses with great distances to the pulse (480, 2000 ms) was observed following active cTBS in participants that were homozygous carriers of the 10-repeat-allele of the DAT1 genotype and had a high resting motor threshold. Our results confirm the importance of the prefrontal cortex for the modulation of PPM. The effects were observed in participants with a high resting motor threshold only, probably because they received a higher dose of cTBS. The effects in homozygous carriers of the DAT1 10-repeat allele confirm the relevance of dopamine for PPM. Conducting an exploratory study we decided against the use of a correction for multiple testing.


Subject(s)
Dopamine Plasma Membrane Transport Proteins/genetics , Evoked Potentials, Motor/physiology , Prefrontal Cortex/physiology , Prepulse Inhibition/physiology , Reflex, Startle/physiology , Theta Rhythm/physiology , Transcranial Magnetic Stimulation/methods , Adult , Female , Genotype , Humans , Male , Minisatellite Repeats , Polymorphism, Genetic , Young Adult
12.
Nervenarzt ; 88(9): 1036-1043, 2017 Sep.
Article in German | MEDLINE | ID: mdl-27629999

ABSTRACT

The use of modern communication and information technology in the health sector, known as eHealth, has the potential to reduce gaps in psychiatric and psychotherapeutic healthcare. In order to successfully implement eHealth it is important to assess the attitude of all stakeholders. The attitude of the patients towards eHealth has been frequently investigated but there is a lack of research on the side of the professionals. The attitude towards eHealth from the perspective of professionals has only rarely been evaluated in German-speaking countries; therefore, we carried out a survey at the German Association for Psychiatry, Psychotherapy and Psychosomatics (DGPPN) congress in 2014 that included 282 psychiatrists, neurologists and psychologists in order to explore their attitudes towards eHealth . Furthermore, the professionals were asked in which therapeutic areas, for which age groups and for which clinical pictures they would expect benefits. In general, the participants expressed a positive attitude towards eHealth . They expected benefits for a multitude of therapeutic areas, particularly for adolescents and adults and especially for the treatment of depression and anxiety disorders; however, they felt only minimally informed about eHealth opportunities indicating a high need for educational and training requirements.


Subject(s)
Attitude of Health Personnel , Psychiatry , Psychotherapy , Telemedicine , Adolescent , Adult , Aged , Anxiety Disorders/diagnosis , Anxiety Disorders/psychology , Anxiety Disorders/therapy , Child , Depressive Disorder/diagnosis , Depressive Disorder/psychology , Depressive Disorder/therapy , Feeding and Eating Disorders/diagnosis , Feeding and Eating Disorders/psychology , Feeding and Eating Disorders/therapy , Female , Humans , Male , Middle Aged , Patient Satisfaction , Pilot Projects , Psychiatry/statistics & numerical data , Psychotherapy/statistics & numerical data , Psychotic Disorders/diagnosis , Psychotic Disorders/psychology , Psychotic Disorders/therapy , Substance-Related Disorders/diagnosis , Substance-Related Disorders/psychology , Substance-Related Disorders/therapy , Surveys and Questionnaires , Telemedicine/statistics & numerical data , Young Adult
13.
Psychol Med ; 46(2): 277-90, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26355299

ABSTRACT

BACKGROUND: Neuroimaging traits of either familial or environmental risk for major depressive disorder (MDD) have been interpreted as possibly useful vulnerability markers. However, the simultaneous occurrence of familial and environmental risk might prove to be a major obstacle in the attempt of recent studies to confine the precise impact of each of these conditions on brain structure. Moreover, the exclusive use of group-level analyses does not permit prediction of individual illness risk which would be the basic requirement for the clinical application of imaging vulnerability markers. Hence, we aimed to distinguish between brain structural characteristics of familial predisposition and environmental stress by using both group- and individual-level analyses. METHOD: We investigated grey matter alterations between 20 healthy control subjects (HC) and 20 MDD patients; 16 healthy first-degree relatives of MDD patients (FH+) and 20 healthy subjects exposed to former childhood maltreatment (CM+) by using a combined VBM/pattern recognition approach. RESULTS: We found similar grey matter reductions in the insula and the orbitofrontal cortex in patients and FH+ subjects and in the hippocampus in patients and CM+ subjects. No direct overlap in grey matter alterations was found between FH+ and CM+ subjects. Pattern classification successfully detected subjects at risk for the disease even by strictly focusing on morphological traits of MDD. CONCLUSIONS: Familial and environmental risk factors for MDD are associated with differing morphometric anomalies. Pattern recognition might be a promising instrument in the search for and future application of vulnerability markers for MDD.


Subject(s)
Adult Survivors of Child Abuse/psychology , Brain/pathology , Depressive Disorder, Major/pathology , Environment , Family , Adult , Case-Control Studies , Cerebral Cortex/pathology , Depressive Disorder, Major/genetics , Depressive Disorder, Major/psychology , Female , Gray Matter/pathology , Hippocampus/pathology , Humans , Image Processing, Computer-Assisted , Magnetic Resonance Imaging , Male , Middle Aged , Neuroimaging , Organ Size , Pattern Recognition, Automated , Prefrontal Cortex/pathology , Risk Factors , Young Adult
14.
Mol Psychiatry ; 20(3): 398-404, 2015 Mar.
Article in English | MEDLINE | ID: mdl-24776739

ABSTRACT

In two large genome-wide association studies, an intergenic single-nucleotide polymorphism (SNP; rs7294919) involved in TESC gene regulation has been associated with hippocampus volume. Further characterization of neurobiological effects of the TESC gene is warranted using multimodal brain-wide structural and functional imaging. Voxel-based morphometry (VBM8) was used in two large, well-characterized samples of healthy individuals of West-European ancestry (Münster sample, N=503; SHIP-TREND, N=721) to analyze associations between rs7294919 and local gray matter volume. In subsamples, white matter fiber structure was investigated using diffusion tensor imaging (DTI) and limbic responsiveness was measured by means of functional magnetic resonance imaging (fMRI) during facial emotion processing (N=220 and N=264, respectively). Furthermore, gene x environment (G × E) interaction and gene x gene interaction with SNPs from genes previously found to be associated with hippocampal size (FKBP5, Reelin, IL-6, TNF-α, BDNF and 5-HTTLPR/rs25531) were explored. We demonstrated highly significant effects of rs7294919 on hippocampal gray matter volumes in both samples. In whole-brain analyses, no other brain areas except the hippocampal formation and adjacent temporal structures were associated with rs7294919. There were no genotype effects on DTI and fMRI results, including functional connectivity measures. No G × E interaction with childhood maltreatment was found in both samples. However, an interaction between rs7294919 and rs2299403 in the Reelin gene was found that withstood correction for multiple comparisons. We conclude that rs7294919 exerts highly robust and regionally specific effects on hippocampal gray matter structures, but not on other neuropsychiatrically relevant imaging markers. The biological interaction between TESC and RELN pointing to a neurodevelopmental origin of the observed findings warrants further mechanistic investigations.


Subject(s)
Calcium-Binding Proteins/genetics , Gray Matter , Hippocampus/anatomy & histology , Polymorphism, Single Nucleotide/genetics , Adolescent , Adult , Aged , Aged, 80 and over , Cell Adhesion Molecules, Neuronal/genetics , Cell Adhesion Molecules, Neuronal/metabolism , Epistasis, Genetic , Extracellular Matrix Proteins/genetics , Extracellular Matrix Proteins/metabolism , Female , Gene Expression Regulation/genetics , Gene-Environment Interaction , Genome-Wide Association Study , Genotype , Gray Matter/blood supply , Gray Matter/metabolism , Hippocampus/blood supply , Humans , Image Processing, Computer-Assisted , Male , Middle Aged , Nerve Tissue Proteins/genetics , Nerve Tissue Proteins/metabolism , Oxygen/blood , Reelin Protein , Serine Endopeptidases/genetics , Serine Endopeptidases/metabolism , Young Adult
15.
Nervenarzt ; 87(9): 1017-29, 2016 Sep.
Article in German | MEDLINE | ID: mdl-27531211

ABSTRACT

Late-onset depression (LOD) is defined as depression manifesting for the first time in later life. Up to now, there has been no exact definition of the lower age limit for LOD. Psychopathological symptoms of LOD do not fundamentally differ from depression in other phases of life; however, cognitive deficits are typically more pronounced. The LOD is associated with an increased risk of developing dementia. Imaging studies show reduction in gray matter volume and white matter lesions caused by vascular diseases. The occurrence of depression with vascular lesions of the brain is also referred to as "vascular depression". The diagnostic procedure includes a detailed medical history and the observation of psychopathological changes, physical examination, laboratory tests, electroencephalograph (EEG), electrocardiograph (ECG) and magnetic resonance imaging (MRI) of the head and neuropsychological tests to measure cognitive deficits. Psychotherapy is an effective treatment option. Selective serotonin reuptake inhibitors are the first-line pharmacological therapy.


Subject(s)
Depression/diagnosis , Depression/therapy , Diagnostic Techniques, Neurological , Geriatric Assessment/methods , Late Onset Disorders/diagnosis , Late Onset Disorders/therapy , Aged , Aged, 80 and over , Combined Modality Therapy/methods , Depression/psychology , Female , Humans , Late Onset Disorders/psychology , Male , Middle Aged , Physical Examination/methods , Psychotherapy/methods , Selective Serotonin Reuptake Inhibitors/therapeutic use
16.
Psychol Med ; 45(8): 1675-85, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25482960

ABSTRACT

BACKGROUND: Previous studies of the dimensional structure of panic attack symptoms have mostly identified a respiratory and a vestibular/mixed somatic dimension. Evidence for additional dimensions such as a cardiac dimension and the allocation of several of the panic attack symptom criteria is less consistent. Clarifying the dimensional structure of the panic attack symptoms should help to specify the relationship of potential risk factors like anxiety sensitivity and fear of suffocation to the experience of panic attacks and the development of panic disorder. METHOD: In an outpatient multicentre study 350 panic patients with agoraphobia rated the intensity of each of the ten DSM-IV bodily symptoms during a typical panic attack. The factor structure of these data was investigated with nonlinear confirmatory factor analysis (CFA). The identified bodily symptom dimensions were related to panic cognitions, anxiety sensitivity and fear of suffocation by means of nonlinear structural equation modelling (SEM). RESULTS: CFA indicated a respiratory, a vestibular/mixed somatic and a cardiac dimension of the bodily symptom criteria. These three factors were differentially associated with specific panic cognitions, different anxiety sensitivity facets and suffocation fear. CONCLUSIONS: Taking into account the dimensional structure of panic attack symptoms may help to increase the specificity of the associations between the experience of panic attack symptoms and various panic related constructs.


Subject(s)
Anxiety Disorders/epidemiology , Fear/psychology , Panic Disorder/epidemiology , Phobic Disorders/epidemiology , Adolescent , Adult , Aged , Agoraphobia , Airway Obstruction , Anxiety Disorders/psychology , Chest Pain , Chills , Cognition , Comorbidity , Dyspnea , Factor Analysis, Statistical , Female , Germany/epidemiology , Humans , Male , Middle Aged , Nausea , Panic Disorder/psychology , Phobic Disorders/psychology , Psychiatric Status Rating Scales , Risk Factors , Sensation Disorders/epidemiology , Sensation Disorders/psychology , Surveys and Questionnaires , Sweating , Young Adult
17.
Mol Psychiatry ; 19(1): 122-8, 2014 Jan.
Article in English | MEDLINE | ID: mdl-23319006

ABSTRACT

Panic disorder with agoraphobia (PD/AG) is a prevalent mental disorder featuring a substantial complex genetic component. At present, only a few established risk genes exist. Among these, the gene encoding monoamine oxidase A (MAOA) is noteworthy given that genetic variation has been demonstrated to influence gene expression and monoamine levels. Long alleles of the MAOA-uVNTR promoter polymorphism are associated with PD/AG and correspond with increased enzyme activity. Here, we have thus investigated the impact of MAOA-uVNTR on therapy response, behavioral avoidance and brain activity in fear conditioning in a large controlled and randomized multicenter study on cognitive behavioral therapy (CBT) in PD/AG. The study consisted of 369 PD/AG patients, and genetic information was available for 283 patients. Carriers of the risk allele had significantly worse outcome as measured by the Hamilton Anxiety scale (46% responders vs 67%, P=0.017). This was accompanied by elevated heart rate and increased fear during an anxiety-provoking situation, that is, the behavioral avoidance task. All but one panic attack that happened during this task occurred in risk allele carriers and, furthermore, risk allele carriers did not habituate to the situation during repetitive exposure. Finally, functional neuroimaging during a classical fear conditioning paradigm evidenced that the protective allele is associated with increased activation of the anterior cingulate cortex upon presentation of the CS+ during acquisition of fear. Further differentiation between high- and low-risk subjects after treatment was observed in the inferior parietal lobes, suggesting differential brain activation patterns upon CBT. Taken together, we established that a genetic risk factor for PD/AG is associated with worse response to CBT and identify potential underlying neural mechanisms. These findings might govern how psychotherapy can include genetic information to tailor individualized treatment approaches.


Subject(s)
Cognitive Behavioral Therapy/methods , Minisatellite Repeats/genetics , Monoamine Oxidase/genetics , Panic Disorder/genetics , Panic Disorder/rehabilitation , Agoraphobia/complications , Agoraphobia/rehabilitation , Brain/blood supply , Brain/pathology , Conditioning, Classical/physiology , Electrocardiography , Female , Follow-Up Studies , Gene Frequency , Genotype , Humans , Image Processing, Computer-Assisted , Magnetic Resonance Imaging , Male , Oxygen/blood , Panic Disorder/complications , Panic Disorder/pathology , Psychiatric Status Rating Scales
18.
Psychol Med ; 44(11): 2385-96, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24398049

ABSTRACT

BACKGROUND: Panic disorder with agoraphobia is characterized by panic attacks and anxiety in situations where escape might be difficult. However, neuroimaging studies specifically focusing on agoraphobia are rare. Here we used functional magnetic resonance imaging (fMRI) with disorder-specific stimuli to investigate the neural substrates of agoraphobia. METHOD: We compared the neural activations of 72 patients suffering from panic disorder with agoraphobia with 72 matched healthy control subjects in a 3-T fMRI study. To isolate agoraphobia-specific alterations we tested the effects of the anticipation and perception of an agoraphobia-specific stimulus set. During fMRI, 48 agoraphobia-specific and 48 neutral pictures were randomly presented with and without anticipatory stimulus indicating the content of the subsequent pictures (Westphal paradigm). RESULTS: During the anticipation of agoraphobia-specific pictures, stronger activations were found in the bilateral ventral striatum and left insula in patients compared with controls. There were no group differences during the perception phase of agoraphobia-specific pictures. CONCLUSIONS: This study revealed stronger region-specific activations in patients suffering from panic disorder with agoraphobia in anticipation of agoraphobia-specific stimuli. Patients seem to process these stimuli more intensively based on individual salience. Hyperactivation of the ventral striatum and insula when anticipating agoraphobia-specific situations might be a central neurofunctional correlate of agoraphobia. Knowledge about the neural correlates of anticipatory and perceptual processes regarding agoraphobic situations will help to optimize and evaluate treatments, such as exposure therapy, in patients with panic disorder and agoraphobia.


Subject(s)
Agoraphobia/physiopathology , Anticipation, Psychological/physiology , Cerebral Cortex/physiopathology , Panic Disorder/physiopathology , Ventral Striatum/physiopathology , Adult , Agoraphobia/epidemiology , Comorbidity , Humans , Magnetic Resonance Imaging , Middle Aged , Panic Disorder/epidemiology
19.
Psychol Med ; 44(2): 381-94, 2014 Jan.
Article in English | MEDLINE | ID: mdl-23611156

ABSTRACT

BACKGROUND: Although several neurophysiological models have been proposed for panic disorder with agoraphobia (PD/AG), there is limited evidence from functional magnetic resonance imaging (fMRI) studies on key neural networks in PD/AG. Fear conditioning has been proposed to represent a central pathway for the development and maintenance of this disorder; however, its neural substrates remain elusive. The present study aimed to investigate the neural correlates of fear conditioning in PD/AG patients. METHOD: The blood oxygen level-dependent (BOLD) response was measured using fMRI during a fear conditioning task. Indicators of differential conditioning, simple conditioning and safety signal processing were investigated in 60 PD/AG patients and 60 matched healthy controls. RESULTS: Differential conditioning was associated with enhanced activation of the bilateral dorsal inferior frontal gyrus (IFG) whereas simple conditioning and safety signal processing were related to increased midbrain activation in PD/AG patients versus controls. Anxiety sensitivity was associated positively with the magnitude of midbrain activation. CONCLUSIONS: The results suggest changes in top-down and bottom-up processes during fear conditioning in PD/AG that can be interpreted within a neural framework of defensive reactions mediating threat through distal (forebrain) versus proximal (midbrain) brain structures. Evidence is accumulating that this network plays a key role in the aetiopathogenesis of panic disorder.


Subject(s)
Agoraphobia/physiopathology , Conditioning, Psychological/physiology , Fear/physiology , Panic Disorder/physiopathology , Adult , Agoraphobia/epidemiology , Cerebral Cortex/physiopathology , Comorbidity , Conditioning, Psychological/classification , Female , Functional Neuroimaging , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Panic Disorder/epidemiology
20.
Nat Genet ; 11(3): 321-4, 1995 Nov.
Article in English | MEDLINE | ID: mdl-7581457

ABSTRACT

Schizophrenia is thought to be a multifactorial disease with complex mode of inheritance. Using a two-stage strategy for another complex disorder, a number of putative IDDM-susceptibility genes have recently been mapped. We now report the results of a two-stage genome-wide search for genes conferring susceptibility to schizophrenia. In stage I, model-free linkage analyses of large pedigrees from Iceland, a geographical isolate, revealed 26 loci suggestive of linkage. In stage II, ten of these were followed-up in a second international collaborative study comprising families from Austria, Canada, Germany, Italy, Scotland, Sweden, Taiwan and the United States. Potential linkage findings of stage I on chromosomes 6p, 9 and 20 were observed again in the second sample. Furthermore, in a third sample from China, fine mapping of the 6p region by association studies also showed evidence for linkage or linkage disequilibrium. Combining our results with other recent findings revealed significant evidence for linkage to an area distal of the HLA region on chromosome 6p. However, in a fourth sample from Europe, the 6p fine mapping finding observed in the Chinese sample could not be replicated. Finally, evidence suggestive of locus heterogeneity and oligogenic transmission in schizophrenia was obtained.


Subject(s)
Genetic Linkage , Schizophrenia/genetics , Chromosomes, Human, Pair 20 , Chromosomes, Human, Pair 6 , Chromosomes, Human, Pair 9 , Disease Susceptibility , Genetic Heterogeneity , Genetic Markers , Genome, Human , Humans , Pedigree , Schizophrenia/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL